 Immutep NASDAQ: IMMP announces a second clinical trial collaboration and supply agreement with Merck Co Inc NYSE: MRK. Under the agreement, Immutep will conduct a new Phase 2B clinical trial in 1st line head and neck squamous cell carcinoma HNSCC patients. 